Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

[1]  C. Bokemeyer,et al.  FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.

[2]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[3]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Russo,et al.  Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario , 2015, Expert opinion on biological therapy.

[5]  M. D'Angelica,et al.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases , 2014, Cancer.

[6]  A. Russo,et al.  The role of targeted therapy for gastrointestinal tumors , 2014, Expert review of gastroenterology & hepatology.

[7]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[8]  J. Hecht,et al.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Hyungjoo Kim,et al.  The BRAF mutation is associated with the prognosis in colorectal cancer , 2014, Journal of Cancer Research and Clinical Oncology.

[10]  A. Russo,et al.  How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? , 2014, Expert opinion on biological therapy.

[11]  G. Fontanini,et al.  BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts). , 2014 .

[12]  M. Choti,et al.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases , 2013, Cancer.

[13]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[14]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[15]  A. Russo,et al.  Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting , 2013, Expert opinion on therapeutic targets.

[16]  A. Russo,et al.  Monoclonal antibodies in gastrointestinal cancers , 2013, Expert opinion on biological therapy.

[17]  T. Gruenberger,et al.  KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab , 2012, The British journal of surgery.

[18]  C. Bokemeyer,et al.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Shung-Haur Yang,et al.  BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy , 2012, Journal of surgical oncology.

[21]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[22]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[23]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[24]  T. Price,et al.  Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Lambrechts,et al.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.

[26]  T. Chua,et al.  Predictors of cure after hepatic resection of colorectal liver metastases: An analysis of actual 5‐ and 10‐year survivors , 2011, Journal of surgical oncology.

[27]  Roger Berry,et al.  KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer , 2011, Clinical Cancer Research.

[28]  C. Ficorella,et al.  EGFR genomic alterations in cancer: prognostic and predictive values. , 2011, Frontiers in bioscience.

[29]  A. Russo,et al.  Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? , 2010, Cancer treatment reviews.

[30]  H. Kennecke,et al.  Patterns of Referral and Resection Among Patients with Liver-Only Metastatic Colorectal Cancer (MCRC) , 2010, Annals of Surgical Oncology.

[31]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[32]  I. Nagtegaal,et al.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. , 2010, European journal of cancer.

[33]  A. Russo,et al.  The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway , 2010, Oncology.

[34]  N. Kemeny,et al.  KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[35]  J. Barrett,et al.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Makuuchi,et al.  The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. , 2009, Critical reviews in oncology/hematology.

[37]  A. Benson,et al.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer. , 2009, Gastrointestinal cancer research : GCR.

[38]  M. Choti,et al.  Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 1669 Patients , 2009, Annals of surgery.

[39]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[41]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Takada,et al.  Proposal of a new and simple staging system of colorectal liver metastasis. , 2006, World journal of gastroenterology.

[44]  T. Takada,et al.  Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. , 2006, World journal of gastroenterology.

[45]  R. Parks,et al.  Guidelines for resection of colorectal cancer liver metastases , 2006, Gut.

[46]  D. Hedley,et al.  Raf kinase as a target for anticancer therapeutics , 2005, Molecular Cancer Therapeutics.

[47]  G. Maddern,et al.  The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. , 2004, Archives of surgery.

[48]  Michael A. Choti,et al.  Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases , 2002, Annals of surgery.

[49]  I. Macdonald,et al.  Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. , 2002, Cancer research.

[50]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[51]  M. Wigler,et al.  Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Russo,et al.  Prognostic significance of proliferative activity, DNA‐ploidy, p53 and Ki‐ras point mutations in colorectal liver metastases , 1998, Cell proliferation.

[53]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[54]  M. Maggard,et al.  K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. , 1995, Archives of surgery.

[55]  K. Omura,et al.  Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity , 1994, Journal of surgical oncology.

[56]  H. Rabes,et al.  K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.